BW-20805 is under clinical development by Shanghai Argo Pharmaceutical and currently in Phase I for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase I drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BW-20805’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BW-20805 overview
BW-20805 is under development for the treatment of hereditary angioedema. It targeting plasma prekallikren (PKK). The drug candidate is administered through subcutaneous route as solution.
Shanghai Argo Pharmaceutical overview
Shanghai Argo Pharmaceutical (Argo Biopharma) is a clinical stage biotech company that develops a new generation of siRNA drugs to provide better treatment for patients. The company develops and utilizes siRNA platform technology RADS (RNA molecules with superior Activity, Durability, and Safety) for the drug development. Its drug pipeline portfolio includes BW-01, BW-02, BW-05, BW-07, BW-32, BW-34, PKK, TMPRSS6, TTR, HBV, INHBE, PNPLA3, HSD17B13, CIDEB, BWS-2, BWS-3, BWS-4, BWS-7, BWS-8, BWS-9, and others. The company is developing drugs to treat cardiovascular diseases, rare diseases, CNS disorders, viral hepatitis, metabolic conditions, hematology disorders, stargardt disease, obesity, metabolic syndrome, NASH, huntington’s disease, alzheimer’s disease, parkinson’s disease, rare diseases, and other undisclosed diseases. Argo Biopharma is headquartered in Shanghai, China.
For a complete picture of BW-20805’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
